News | September 10, 2024
Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Agreement further expands Aptar Pharma’s leading respiratory portfolio
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The companies will leverage their respective proprietary technology platforms
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
New facility is part of Aptar Pharma’s global expansion program
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
Subscribe To Our Newsletter & Stay Updated
